{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:42:55Z","timestamp":1791218575965,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00111\/2013"],"award-info":[{"award-number":["IF\/00111\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/118408\/2016"],"award-info":[{"award-number":["SFRH\/BPD\/118408\/2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007038"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007038"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.drudis.2018.01.033","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T13:24:50Z","timestamp":1515763490000},"page":"736-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Safinamide: a new hope for Parkinson\u2019s disease?"],"prefix":"10.1016","volume":"23","author":[{"given":"F\u00e1bio G.","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Silva","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio J.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2018.01.033_bib0005","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/brain\/awu381","article-title":"Dopaminergic modulation of motor network dynamics in Parkinson\u2019s disease","volume":"138","author":"Michely","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2018.01.033_bib0010","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0015","first-page":"19","article-title":"Parkinson revisited: pathophysiology of motor signs","volume":"91","author":"Hallett","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3233\/NRE-171444","article-title":"Axial rigidity is related to the risk of falls in patients with Parkinson\u2019s disease","volume":"40","author":"Cano-de-la-Cuerda","year":"2017","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.drudis.2018.01.033_bib0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/0004-282X20160074","article-title":"Postural instability and falls are more frequent in Parkinson\u2019s disease patients with worse trunk mobility","volume":"74","author":"Artigas","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.drudis.2018.01.033_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0404.2010.01386.x","article-title":"Recurrent falls and mortality in Parkinson\u2019s disease: a prospective two-year follow-up study","volume":"123","author":"Matinolli","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.drudis.2018.01.033_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/eb-2016-102574","article-title":"Cognitive-behavioural therapy for non-motor symptoms of Parkinson\u2019s disease: a clinical review","volume":"20","author":"Koychev","year":"2017","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.drudis.2018.01.033_bib0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jad.2015.05.059","article-title":"Depression rating scales in Parkinson\u2019s disease: a critical review updating recent literature","volume":"184","author":"Torbey","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1590\/0004-282X20150029","article-title":"Non-motor signs in Parkinson\u2019s disease: a review","volume":"73","author":"Munhoz","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.drudis.2018.01.033_bib0050","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1590\/0004-282X20150029","article-title":"Non-motor signs in Parkinson\u2019s disease: a review","volume":"73","author":"Munhoz","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.drudis.2018.01.033_bib0055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/18715273113129990086","article-title":"Motor complications in Parkinson\u2019s disease: a comprehensive review of emergent management strategies","volume":"12","author":"Marques de Sousa","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.drudis.2018.01.033_bib0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1586\/ern.09.117","article-title":"Current strategies in the treatment of Parkinson\u2019s disease and a personalized approach to management","volume":"9","author":"Diaz","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.drudis.2018.01.033_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/14737175.6.1.91","article-title":"Parkinson\u2019s disease management strategies","volume":"6","author":"Rajput","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.drudis.2018.01.033_bib0070","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","article-title":"An expert opinion on safinamide in Parkinson\u2019s disease","volume":"17","author":"Onofrj","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2018.01.033_bib0075","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00018-016-2141-1","article-title":"Parkinson\u2019s disease: towards better preclinical models and personalized treatments","volume":"73","author":"Lindholm","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.drudis.2018.01.033_bib0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X14666151120123025","article-title":"Current pharmaceutical treatments and alternative therapies of Parkinson\u2019s disease","volume":"14","author":"Dong","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/17512433.2014.966812","article-title":"New treatments for the motor symptoms of Parkinson\u2019s disease","volume":"7","author":"Vijverman","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mds.26890","article-title":"Current applications and limitations of surgical treatments for movement disorders","volume":"32","author":"Krack","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuropharm.2012.05.026","article-title":"Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson\u2019s disease","volume":"66","author":"Amalric","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000362419","article-title":"Advances in drug development for Parkinson\u2019s disease: present status","volume":"93","author":"Harikrishna Reddy","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2015.06.028","article-title":"GM1 ganglioside in Parkinson\u2019s disease: pilot study of effects on dopamine transporter binding","volume":"356","author":"Schneider","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.drudis.2018.01.033_bib0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/ars.2013.5801","article-title":"Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson\u2019s disease?","volume":"21","author":"Seet","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.drudis.2018.01.033_bib0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.05.010","article-title":"Emerging therapies for Parkinson\u2019s disease: from bench to bedside","volume":"144","author":"Tarazi","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.01.033_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s13311-013-0233-2","article-title":"Gene-based therapies in Parkinson\u2019s disease","volume":"11","author":"Allen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2018.01.033_bib0125","doi-asserted-by":"crossref","first-page":"e0149776","DOI":"10.1371\/journal.pone.0149776","article-title":"Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson\u2019s disease","volume":"11","author":"Garea-Rodriguez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2018.01.033_bib0130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4103\/1673-5374.180739","article-title":"Paracrine factors for neurodegenerative disorders: special emphasis on Parkinson\u2019s disease","volume":"11","author":"Di Santo","year":"2016","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.drudis.2018.01.033_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrneurol.2016.196","article-title":"Precision medicine for disease modification in Parkinson disease","volume":"13","author":"Espay","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nan.12263","article-title":"Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"42","author":"Sadeghian","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0145","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.2014.897694","article-title":"Safinamide for the treatment of Parkinson\u2019s disease","volume":"23","author":"Dezsi","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2018.01.033_bib0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/nmt.15.46","article-title":"Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease","volume":"5","author":"Fabbri","year":"2015","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.drudis.2018.01.033_bib0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","article-title":"Safinamide: a review in Parkinson\u2019s disease","volume":"31","author":"Blair","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2018.01.033_bib0160","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/TCRM.S86393","article-title":"Emerging approaches in Parkinson\u2019s disease \u2014 adjunctive role of safinamide","volume":"12","author":"Muller","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.drudis.2018.01.033_bib0165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/DDDT.S77749","article-title":"Adjuvant therapies for Parkinson\u2019s disease: critical evaluation of safinamide","volume":"10","author":"Stocchi","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.drudis.2018.01.033_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17925\/ENR.2015.10.01.15","article-title":"Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson\u2019s disease","volume":"10","author":"Schnitker","year":"2015","journal-title":"Eur. Neurol. Rev."},{"key":"10.1016\/j.drudis.2018.01.033_bib0175","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of safinamide","volume":"56","author":"Muller","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2018.01.033_bib0180","first-page":"S287","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2018.01.033_bib0185","first-page":"S18","article-title":"Safinamide: from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0190","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/17425255.2017.1329418","article-title":"Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson\u2019s disease","volume":"13","author":"Muller","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40263-015-0249-8","article-title":"Defining the role of the monoamine oxidase-B inhibitors for Parkinson\u2019s disease","volume":"29","author":"Robakis","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drudis.2018.01.033_bib0200","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.01.033_bib0205","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fphar.2016.00340","article-title":"Inhibitors of MAO-A and MAO-B in psychiatry and neurology","volume":"7","author":"Finberg","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0210","first-page":"450","article-title":"The effect of safinamide, a novel drug for Parkinson\u2019s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial","volume":"92","author":"Marquet","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.01.033_bib0215","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3233\/JPD-150569","article-title":"Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson\u2019s disease: a post-hoc analysis","volume":"5","author":"Cattaneo","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.drudis.2018.01.033_bib0220","first-page":"622","article-title":"Xadago (safinamide): a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson\u2019s disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P. T."},{"key":"10.1016\/j.drudis.2018.01.033_bib0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002826-200307000-00012","article-title":"Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition","volume":"26","author":"Cattaneo","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0230","first-page":"366","article-title":"Pharmaceutical approval update","volume":"42","author":"Choy","year":"2017","journal-title":"P. T."},{"key":"10.1016\/j.drudis.2018.01.033_bib0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrneurol.2010.2","article-title":"Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression","volume":"6","author":"Sampaio","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0240","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"Palhagen","year":"2006","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2018.01.033_bib0245","first-page":"S101","article-title":"Why have we failed to achieve neuroprotection in Parkinson\u2019s disease?","volume":"64","author":"Olanow","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0250","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","article-title":"Neuroprotection trials in Parkinson\u2019s disease: systematic review","volume":"24","author":"Hart","year":"2009","journal-title":"Mov. Disord."},{"issue":"7 Suppl","key":"10.1016\/j.drudis.2018.01.033_bib0255","first-page":"S51","article-title":"\u2018Disease-modification\u2019 trials in Parkinson disease: target populations, endpoints and study design","volume":"72","author":"Rascol","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0260","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","article-title":"A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson\u2019s disease (the ADAGIO study): rationale, design, and baseline characteristics","volume":"23","author":"Olanow","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0265","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease","volume":"46","author":"Parkinson Study Group","year":"1989","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0270","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/01.wnf.0000240956.49315.be","article-title":"Monamine oxidase inhibitors: current and emerging agents for Parkinson disease","volume":"30","author":"Fernandez","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0275","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","author":"Group","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNF.0000000000000167","article-title":"Comparison of selegiline and rasagiline therapies in parkinson disease: a real-life study","volume":"39","author":"Peretz","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0285","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e3181d7d8e2","article-title":"Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?","volume":"74","author":"Ahlskog","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0290","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pbb.2013.01.015","article-title":"Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor","volume":"105","author":"Podurgiel","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drudis.2018.01.033_bib0300","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","article-title":"Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys","volume":"19","author":"Gregoire","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0305","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awt041","article-title":"Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis","volume":"136","author":"Morsali","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2018.01.033_bib0310","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0315","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0320","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0325","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/01.WNL.0000134672.44217.F7","article-title":"Improvement of motor function in early Parkinson disease by safinamide","volume":"63","author":"Stocchi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0330","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.23954","article-title":"A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson\u2019s disease patients","volume":"27","author":"Stocchi","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0335","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1468-1331.2012.03840.x","article-title":"Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease","volume":"20","author":"Schapira","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"Suppl","key":"10.1016\/j.drudis.2018.01.033_bib0340","article-title":"Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION study) (P01.061)","volume":"80","author":"Barone","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2018.01.033_bib0345","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0350","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0355","first-page":"S152","article-title":"Safinamide significantly improves responder rates in fluctuating Parkinson\u2019s disease (PD) patients as add-on to levodopa (SETTLE)","volume":"28","author":"Schapira","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0360","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0365","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-150700","article-title":"Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson\u2019s disease fluctuating patients: post hoc analyses of Studies 016 and SETTLE","volume":"6","author":"Cattaneo","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.drudis.2018.01.033_bib0370","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0375","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/mds.26415","article-title":"New clinical trials for nonmotor manifestations of Parkinson\u2019s disease","volume":"30","author":"Schrag","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl. 17","key":"10.1016\/j.drudis.2018.01.033_bib0380","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1002\/mds.21683","article-title":"Cholinergic and other neurotransmitter mechanisms in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies","volume":"22","author":"Francis","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000010","article-title":"Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study","volume":"37","author":"Emre","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0390","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","article-title":"Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability","volume":"72","author":"Smith","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0395","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0400","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non-motor symptoms of Parkinson\u2019s disease: post hoc analysis of RECOVER","volume":"19","author":"Ray Chaudhuri","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0405","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2018.01.033_bib0410","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","article-title":"Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease","volume":"321","author":"Parkinson Study Group","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.01.033_bib0415","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.drudis.2018.01.033_bib0420","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1002\/ana.10488","article-title":"Neuroprotection in Parkinson\u2019s disease: clinical trials","volume":"53","author":"Stocchi","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","article-title":"SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa","volume":"6","author":"Przuntek","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Parkinson Study Group CALM Cohort Investigators","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0435","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","article-title":"Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial","volume":"12","author":"Schapira","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2018.01.033_bib0440","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","article-title":"The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa","volume":"137","author":"Cilia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2018.01.033_bib0445","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.01.033_bib0450","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cortex.2015.08.005","article-title":"A systematic review on the applications of resting-state fMRI in Parkinson\u2019s disease: does dopamine replacement therapy play a role?","volume":"73","author":"Tahmasian","year":"2015","journal-title":"Cortex"},{"key":"10.1016\/j.drudis.2018.01.033_bib0455","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbadis.2008.09.009","article-title":"Targets for neuroprotection in Parkinson\u2019s disease","volume":"1792","author":"Yacoubian","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drudis.2018.01.033_bib0460","doi-asserted-by":"crossref","first-page":"e00251","DOI":"10.1002\/prp2.251","article-title":"Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson\u2019s disease","volume":"4","author":"Loprete","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.drudis.2018.01.033_bib0465","first-page":"YYY","article-title":"Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia","volume":"XX","author":"Morari","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2018.01.033_bib0470","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1871527316666170124165222","article-title":"Monoamine oxidase B inhibitors in Parkinson\u2019s disease","volume":"16","author":"Dezsi","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.drudis.2018.01.033_bib0475","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1586\/14737175.2013.827488","article-title":"Current status of safinamide for the drug portfolio of Parkinson\u2019s disease therapy","volume":"13","author":"Muller","year":"2013","journal-title":"Expert Rev. Neurother."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617304269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644617304269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:01:52Z","timestamp":1778601712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644617304269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1359644617304269"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.01.033","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safinamide: a new hope for Parkinson\u2019s disease?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}